Starling Oncology’s headquarters:
18000 Studebaker Rd, Suite 800
Cerritos, CA 90703
Starling Oncology outside counsel is Latham & Watkins LLP
Starling Oncology's auditors are BDO USA, LLP
Starling Oncology began trading on November 15, 2021
Starling Oncology ticker symbol is STLN
Starling Oncology trades on the Nasdaq Capital Market (NASDAQ)
Starling Oncology was founded in 2007
Starling Oncology's fiscal year ends on December 31
The company currently does not pay a dividend
Starling Oncology’s transfer agent is Continental Stock Transfer & Trust Company
Starling Oncology’s transfer agent, Continental Stock Transfer & Trust Company, can help you in a variety of shareholder-related services including change of address, lost stock certificates, stock transfer, account status and other administrative services.
You can contact our transfer agent at:
Continental Stock Transfer & Trust Company
By Regular Mail:
1 State St – 30th floor,
New York, NY 10004
Starling Oncology’s investor materials can be viewed or downloaded from this website.
Click Here to view the board of directors
The company does not offer a Direct Stock Purchase Plan
You can contact Starling Oncology Investor Relations via email at investors@theoncologyinstitute.com
Quarterly and annual reports, as well as other SEC filings, can be accessed on the Financials section of the STLN's Investor Relations website: SEC Filings or directly from the SEC: www.sec.gov
Please refer to the Investor Resources section of the IR website and sign up electronically under Email Alerts. You will receive all news releases as soon as they are posted on the website.